1249 Treatment interruptions for immune related adverse events and overall survival in patients with non-small cell lung cancer (NSCLC) treated with first line immune checkpoint inhibitors (ICI)

Evelyn Goodyear,Regan M Memmott ,Jacob J Kaufman ,David P Carbone ,Austin Secor,Yihzen Guo,Daniel J Spakowicz ,Erin M Bertino ,Asrar Alahmadi,Kai He,Peter G Shields ,Gabrielle Lopez,Mingjia Li,Carolyn J Presley ,Parthib Das,Gregory A Otterson ,Nitya Surya,Songzhu Zhao,Marium Husain,Madison Grogan,Lai Wei,Dwight H Owen

doi:10.1136/jitc-2022-sitc2022.1249

1249 Treatment interruptions for immune related adverse events and overall survival in patients with non-small cell lung cancer (NSCLC) treated with first line immune checkpoint inhibitors (ICI)

Evelyn Goodyear, Regan M Memmott + Show 20 more

Open Access

PDF Available

https://doi.org/10.1136/jitc-2022-sitc2022.1249

Copy DOI

Export

Save

Cite

Journal: Journal for ImmunoTherapy of Cancer

Publication Date: Nov 1, 2022

Affiliation: The Ohio State University

#Permanently Discontinued #Immune Checkpoint Inhibitors #Significant Difference In mOS #Treatment Discontinuation #Immune Checkpoint Inhibitors Monotherapy #Treatment Discontinuation In Patients #Overall Survival #Treatment Interruption #Tertiary Cancer Center #Non-small Cell Lung Cancer

Abstract
Full-Text PDF
Similar Papers

Abstract

Listen

BackgroundData from prospective phase 3 trials of anti-PD-1 and anti-CTLA-4 demonstrate durable clinical benefit even in patients who discontinue ICI due to treatment related adverse events. However, outcomes for patients...

Full Text

Published Version (Free)

View/Download pdf

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Journal for ImmunoTherapy of Cancer

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.

R Discovery Prime

1249 Treatment interruptions for immune related adverse events and overall survival in patients with non-small cell lung cancer (NSCLC) treated with first line immune checkpoint inhibitors (ICI)